Wells Fargo & Company Atossa Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Atossa Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 921 shares of ATOS stock, worth $1,234. This represents 0.0% of its overall portfolio holdings.
Number of Shares
921
Previous 910
1.21%
Holding current value
$1,234
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding ATOS
# of Institutions
71Shares Held
19.3MCall Options Held
95KPut Options Held
82.4K-
Vanguard Group Inc Valley Forge, PA5.75MShares$7.71 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.75MShares$3.69 Million0.0% of portfolio
-
Laurion Capital Management LP New York, NY2.23MShares$2.98 Million0.04% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.39MShares$1.86 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.21MShares$1.62 Million0.0% of portfolio
About ATOSSA THERAPEUTICS, INC.
- Ticker ATOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 126,624,000
- Market Cap $170M
- Description
- Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...